Dr. Reddy’s Laboratories and Russian Direct Investment Fund (RDIF) announced that they have commenced adaptive phase 2/3 clinical trials for Sputnik V vaccine in India after receiving the necessary clearance from the Central Drugs Laboratory, Kasauli, India.
Biopharmaceutical company Amgen, along with two other drugmakers Takeda and UCB, has enrolled the first patient in a global platform trial of hospitalised patients with Covid-19.
NeoImmuneTech has dosed the first patient in its phase 1 study designed to assess NT-I7 (efineptakin alfa) in adult patients with mild Covid-19.
Haoma Medica announced the completion of a first-in-human trial for NaQuinate, a naphthoquinone carboxylic acid, which is being developed as a novel orally administered therapeutic for osteoporosis.
Celltrion Group announced enrolment completion of 327 patients with mild-to-moderate symptoms of SARS-CoV-2 infection in the global Phase II clinical trial of CT-P59, an anti-COVID-19 monoclonal antibody treatment candidate. Celltrion anticipates submission for emergency use authorisation (EUA) to the Korean Ministry of Food and Drug Safety (MFDS), conditional on results from the global Phase II pivotal trial.
Roche has secured US FDA approval for its supplemental new drug application (sNDA) for Xofluza (baloxavir marboxil), an oral medicine, to prevent influenza in people 12 years and older following their contact with someone suffering with influenza or post-exposure prophylaxis.
Appili Therapeutics, a biopharmaceutical company focused on anti-infective drug development, today announced initiation of its Phase 3 Post Exposure Prophylaxis for COVID-19 (PEPCO) study to evaluate Avigan tablets (favipiravir) in the prevention of Covid-19.
Apnimed announced that the first patient has been dosed in a Phase 2 clinical trial evaluating AD109, the company’s first-in-class, oral pharmaceutical under development for the treatment of OSA.
City of Hope, the US-based independent biomedical research and treatment centre, has commenced phase 1 clinical trial to evaluate its first SARS-CoV-2 investigational vaccine.
British drugmaker GlaxoSmithKline (GSK) has started patient dosing in a phase 3 clinical trial to assess the safety and efficacy of the respiratory syncytial viirus (RSV) vaccine candidate for maternal immunisation.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.